Bharat Biotech Completes Trials for India’s First Intranasal Covid Vaccine, Calls It Safe and Immunogenic
New Delhi: Bharat Biotech International Limited (BBIL) on Monday announced that its intra-nasal vaccine (BBV154) has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials. “This vaccine candidate was evaluated earlier in phase I and II clinical trials with successful results. BBV154 has been specifically formulated to allow intranasal delivery. In … Read more